title: Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy.
abstract: OBJECTIVE
  Recent prospective studies have shown that the sequential therapy has not achieved the target Helicobacter pylori eradication rate of > 80% in Korea. The aim of this study was to therefore assess the efficacy of the hybrid therapy as a first-line treatment for H. pylori eradication in a prospective trial.
  
  
  METHODS
  From December 2012 to August 2013, 184 patients with confirmed H. pylori infections received either the 14-day hybrid therapy or the 14-day sequential therapy. Eradication outcomes were evaluated using a 13C-urea breath test at least 4 weeks after treatment cessation.
  
  
  RESULTS
  A total of 184 patients (90 receiving hybrid treatment and 94 receiving sequential treatment) completed the study. The eradication rates of the hybrid and sequential therapy groups were 81.1% (73/90; 95% confidence interval [CI] = 73.0-89.2%) and 79.8% (75/94; 95%CI = 71.7-87.9%), respectively, by intention-to-treat analysis (P = 0.821). By per protocol analysis, eradication rates were 85.9% (73/85; 95%CI = 78.5-93.3%) and 82.0% (73/89; 95%CI = 74.0-89.9%; P = 0.489), respectively. There were no significant intergroup differences in treatment compliance or discontinuation induced by severe side effects.
  
  
  CONCLUSIONS
  The hybrid therapy achieved acceptable eradication rate (85.9%), but not statistically significantly higher rates than the sequential therapy (82.0%). Further studies are therefore needed to identify first-line treatments with even better eradication rates in the Korean population.
authors: Dong Hyun
authors: DH
authors: Oh
authors: Dong Ho
authors: DH
authors: Lee
authors: Kyu Keun
authors: KK
authors: Kang
authors: Young Soo
authors: YS
authors: Park
authors: Cheol Min
authors: CM
authors: Shin
authors: Nayoung
authors: N
authors: Kim
authors: Hyuk
authors: H
authors: Yoon
authors: Jin Hyeok
authors: JH
authors: Hwang
authors: Sook Hyang
authors: SH
authors: Jeoung
authors: Jin Wook
authors: JW
authors: Kim
authors: Eun Sun
authors: ES
authors: Jang
authors: Hyun Chae
authors: HC
authors: Jung
mesh_terms: D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage*; D017291:Clarithromycin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005756:Gastritis / Q000188:drug therapy* / Q000382:microbiology*; D016481:Helicobacter Infections / Q000188:drug therapy; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage*; D008875:Middle Aged; D064750:Rabeprazole / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D008795:Metronidazole; D064750:Rabeprazole; D000658:Amoxicillin; D017291:Clarithromycin